Current Headlines

  1. Cyxone Announces Strategic Intent To Position Its Drug Candidate T20K In MS As A Prophylactic Agent
    3/20/2019

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that preclinical findings support the positioning of its drug candidate T20K as a prophylactic agent for the treatment of multiple sclerosis (MS). This indicates that the substance could be used to mitigate or prevent MS episodes and potentially even delay the disease progression. Early disease intervention, such as this, is currently not targeted by other treatments available

  2. Takeda And HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership In Liver Diseases
    3/20/2019

    HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH)

  3. Unique Foods (UPZS) Acquires Pizza Fusion
    3/19/2019

    via NEWMEDIAWIRE -- Unique Foods Corporation (OTCPK: UPZS) today announced that it has acquired privately held Pizza Fusion Holdings Inc. The Pizza Fusion brand will become a wholly owned subsidiary of the parent company Unique Foods Corporation

  4. Ono Pharmaceutical And twoXAR Announce Drug Discovery Research Collaboration
    3/18/2019

    Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced recently that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease

  5. Iktos Announces Collaboration With Merck KGaA, Darmstadt, Germany, For Use Of Iktos AI Technology Across Three Drug Discovery Projects
    3/14/2019

    Iktos, a company specialized in Artificial Intelligence for new drug design, recently announced a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, where Iktos generative modelling artificial intelligence (AI) technology will be used to facilitate the rapid and cost-effective discovery and design of promising new compounds for Merck KGaA, Darmstadt, Germany

  6. Eton Pharmaceuticals Submits New Drug Application For DS-200
    3/14/2019

    Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DS-200 via the Rolling Review process. DS-200 was previously granted Fast Track Designation by the FDA

  7. InMed Pharmaceuticals Announces Transition To A Single Cannabinoid Investigational Drug Candidate - INM-755 - For Its Epidermolysis Bullosa Program
    3/13/2019

    InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a R&D pipeline of medications targeting diseases with high unmet medical needs, today provided an update on its drug development program for the treatment of Epidermolysis Bullosa ("EB")

  8. HitGen And SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
    3/12/2019

    HitGen Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) recently announced a research collaboration to identify novel small molecule leads for targets of interest. Under this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC

  9. CStone Received IND Approval In China For HDAC6 Inhibitor CS3003
    3/12/2019

    CStone Pharmaceuticals (Suzhou) Co., Ltd. ("CStone", stock code: 2616.HK) announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical trial in China

  10. Rosa & Co. Announces Strategic Research Agreement With Chugai Pharmaceutical Co., Ltd.
    3/12/2019

    Rosa & Co. LLC, a drug development advisory firm known worldwide for its PhysioPD™ Research Platforms, today announced the initiation of a long-term Strategic Research Agreement with Chugai Pharmaceutical Co., Ltd. to provide Rosa's PhysioPD research services